Cancer R&D 2024 has wrapped up successfully. We’re grateful for your interest and interaction with Alfa Cytology. We’re eager to continue providing our expertise in cancer drug development. Let’s look back on these memorable moments!
Learn More
Feline leukemia virus (FeLV) infection poses a significant threat to cats, as it can be fatal. Unfortunately, there is currently no effective treatment available to cure FeLV-infected cats. Alfa Cytology is dedicated to advancing the development of effective drugs to combat the feline leukemia virus. Our services focus on research and development efforts aimed at discovering novel therapeutic approaches to treat FeLV-infected cats.
Cats infected with FeLV usually develop FeLV-associated diseases and die within a few years. Numerous drugs, such as feline interferon-ὠ, zidovudine (AZT), and Adefovir, have been studied for their potential effectiveness in treating FeLV-infected cats. However, the outcomes have been discouraging, as these drugs have proven either ineffective or highly toxic, in addition to being prohibitively expensive. In addition to medications, vaccination is one way to manage FeLV. While vaccines offer some protection, they do not guarantee complete immunity against the virus.
Fig. 1. Assembly of feline leukemia virus (FeLV) at the plasma membrane. (Willett, B.J.; Hosie, M.J., 2013)
| Drugs | Service Details |
| Nucleoside analogue reverse transcriptase inhibitors | We conduct drug testing experiments utilizing our offered nucleoside analogs, including zidovudine, stavudine, and didanosine, to assess their activity against FeLV. |
| Nucleotide analogue reverse transcriptase inhibitors | We develop non-nucleoside reverse transcriptase inhibitors as non-competitive inhibitors of reverse transcriptase. Our goal is to determine the mechanism of interaction between these inhibitors and the enzyme's active site, as well as evaluate their activity against FeLV. |
| Non-nucleoside reverse transcriptase inhibitors | We develop non-nucleoside reverse transcriptase inhibitors as non-competitive inhibitors of reverse transcriptase. Our research involves determining the mechanism of interaction between the inhibitor and the enzyme's transition site. Furthermore, we evaluate its activity against FeLV. |
| Nucleotide synthesis inhibitors | We offer services focused on the development of drugs against FeLV, with a particular emphasis on nucleotide synthesis inhibitors. Through our screening process, we can assess the potential of inhibitors that interfere with DNA and RNA synthesis. Our drug testing involves evaluating the therapeutic effects of nucleotide synthesis inhibitors such as Ribavirin and Foscarnet on FeLV. |
| Interferons | We conducted in vivo and in vitro experiments to investigate the effects of Feline interferon-ω and Human interferon-α, and to examine possible therapeutic approaches against feline leukemia virus. |
We offer vaccine development services for FeLV, taking into account the advancements made in FeLV vaccination. Our vaccine development services encompass a range of vaccine types, including adjuvanted killed virus noninfectious vaccines, adjuvanted subunit vaccines, and various combination vaccines. Furthermore, we possess the capability to develop recombinant vaccines with minimized side effects.
Despite the availability of chemotherapy methods, achieving an ideal cure after FeLV infection remains challenging. Collaborate with us to develop an innovative enhanced regimen for inducing remission, aimed at improving the safety and effectiveness of chemotherapy.
Alfa Cytology offers development services for treating feline leukemia. We aim to discover and develop effective treatments to combat FeLV and improve the well-being of affected felines. Let us work together to develop innovative, objective treatments. Contact our committed team for further details or to discuss your unique needs.
Reference